首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   131304篇
  免费   9231篇
  国内免费   455篇
耳鼻咽喉   1657篇
儿科学   3544篇
妇产科学   2242篇
基础医学   17052篇
口腔科学   2450篇
临床医学   13471篇
内科学   27724篇
皮肤病学   2012篇
神经病学   12526篇
特种医学   4614篇
外国民族医学   4篇
外科学   18867篇
综合类   2034篇
现状与发展   1篇
一般理论   177篇
预防医学   11868篇
眼科学   3074篇
药学   9204篇
  2篇
中国医学   174篇
肿瘤学   8293篇
  2023年   537篇
  2022年   872篇
  2021年   2152篇
  2020年   1284篇
  2019年   2113篇
  2018年   2428篇
  2017年   1870篇
  2016年   2066篇
  2015年   2513篇
  2014年   3582篇
  2013年   5537篇
  2012年   8084篇
  2011年   8587篇
  2010年   4876篇
  2009年   4652篇
  2008年   8297篇
  2007年   8870篇
  2006年   8681篇
  2005年   8936篇
  2004年   8452篇
  2003年   8253篇
  2002年   7802篇
  2001年   1417篇
  2000年   1159篇
  1999年   1436篇
  1998年   1798篇
  1997年   1495篇
  1996年   1238篇
  1995年   1210篇
  1994年   1015篇
  1993年   1007篇
  1992年   935篇
  1991年   877篇
  1990年   842篇
  1989年   792篇
  1988年   712篇
  1987年   687篇
  1986年   686篇
  1985年   805篇
  1984年   895篇
  1983年   924篇
  1982年   1215篇
  1981年   1101篇
  1980年   1014篇
  1979年   545篇
  1978年   627篇
  1977年   608篇
  1976年   520篇
  1975年   475篇
  1974年   433篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

5.
6.
7.
8.

Background

Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.

Methods

Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.

Results

Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).

Conclusions

Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号